Citations

Clear

31 citation(s) found for "Shin, John".

Unmasking Racial, Ethnic, and Socioeconomic Disparities in United States Chordoma Clinical Trials: Systematic Review
Bangash, Ali Haider , Ryvlin, Jessica , Chakravarthy, Vikram , Sullivan, Patricia L. Zadnik, Niu, Tianyi , Galgano, Michael , Shin, John H., Gokaslan, Ziya L. , Fourman, Mitchell S. , Gelfand, Yaroslav , Murthy, Saikiran G. , Yassari, Reza , Galgano, Michael A , Fourman, Mitchell S , De la Garza Ramos, Rafael , Bangash, Ali Haider , Akinduro, Oluwaseun O. , Sullivan, Patricia Zadnik , Ramos, Rafael De la Garza

Mayo Clinic

Cancers | January 13, 2025 | Volume: 17 | Issue: 2 | Pages: 225

10.3390/cancers17020225 | PMID 39858008 Get It

Background: Chordoma is a rare bone cancer with limited treatment options. Clinical trials are crucial for developing effective therapies, but their success depends on including diverse patient populations. The objective of this study was to systematically evaluate the reporting of racial, ethnic, and socioeconomic diversity in United States clinical trials exploring treatment for chordoma. Methods: A literature search was conducted through PubMed/Medline, Cochrane, Epistemonikos, and ClinicalTrials.gov databases for published US chordoma trials up until 19 August 2024. The data collected included trial characteristics and racial and ethnic data, as well as socioeconomic indicators when available. Methodological Index for Non-Randomized Studies (MINORS) and Revised Cochrane Risk-of-Bias Tool for Randomized Trials (RoB2) analyses were adopted to assess the methodological quality. The N-1 Chi-squared (χ2) test was implemented to compare the reported racial and ethnic data with the most recent US Census Bureau data. Results: Five trials involving 111 patients (median age: 63 years; 34% female) were included. Four studies (80%) were single-arm non-randomized studies with one study (25%) having a high methodological quality and three (75%) having a moderate quality based on the MINORS analysis. Most patients (91%, n = 82) were White/Caucasian, representing a proportion which was significantly higher than the reported 75% in the US population (p = 0.0005). Black/African American patients (2%, n = 2) were significantly underrepresented compared to the 14% in the US population (p = 0.0015). Regarding ethnicity, Hispanic/Latino patients (7%, n = 6) were significantly underrepresented compared to the 20% in the US population (p = 0.0021). No measures of socioeconomic status were reported. Conclusions: This systematic review highlighted the need for improved racial and ethnic diversity in chordoma trials and the better reporting of socioeconomic data. The underrepresentation of minority groups may obscure potential disparities in disease incidence, treatment access, and clinical outcomes.
Role of Posterior Carbon Fiber Implants in Spine Tumor Surgery
Alvarez‐Breckenridge, Christopher , North, Robert Y. , Lo, Sheng-Fu Larry , Mohammed, Karim, Reynolds, Jeremy , Lazáry, Áron , Laufer, Ilya , Verlaan, Jorrit Jan, Gokaslan, Ziya L., Cecchinato, Riccardo , Disch, Alexander C. , Goodwin, Matthew L. , Sahgal, Arjun , Alvarez-Breckenridge, Christopher , Reynolds, Jeremy , Lazary, Aron , Disch, Alexander , Goodwin, C Rory , Tatsui, Claudio Esteves , Kumar, Naresh P. , Mohammed, Karim, Verlaan, Jorrit‐Jan , Luzzati, Alessandro , Shin, John H. , Hornicek, Francis J. , Goodwin, C. Rory , Gasbarrini, Alessandro , Boriani, Stefano

Mayo Clinic

Global Spine Journal | January 13, 2025 | Volume: 15 | Issue: 1_suppl | Pages: No page available

10.1177/21925682241259778 | PMID 39801115 Get It

Study Design Narrative Review. Objective The management of spinal tumors requires a multi-disciplinary approach including surgery, radiation, and systemic therapy. Surgical approaches typically require posterior segmental instrumentation to maintain long-term spinal stability. Carbon fiber reinforced pedicle screws (CFRP) are increasingly used in the oncologic setting due to reductions in both imaging artifacts and radiotherapy perturbations compared to titanium implants. We performed a review of the literature and highlight advantages and future areas of study for CFRP. Methods We performed a systematic review of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and identified 10 articles including 573 patients. Across all studies we reviewed patient demographics, tumor types treated, hardware-related features, complication rates, recurrence, survival, and follow-up. Results Across 10 studies, a total of 1371 screws placed. Surgical and non-surgical complications were reported in 18.3% of patients. Disease progression at the surgical site was detected in 7.3% of patients. There was no significant difference in clinical or hardware complications between CFRP or titanium implants. The most frequent complication attributable to implanted CFRP hardware included screw breakage in 2.4% and loosening in 1.7% of patients, respectively. Conclusion CFRP provide a unique tool in the setting of spinal oncology. With a safety profile comparable to titanium, we review the documented advantages of CFRP posterior implants compared to titanium, while also addressing their current limitations. Additionally, we highlight several areas of future research to identify the optimal patients who will achieve the greatest benefit of CFRP.
Gender and Sex Differences in Health-related Quality of Life, Clinical Outcomes and Survival after Treatment of Metastatic Spine Disease
Price, Meghan , Goodwin, Andrea N. , Dalton, Tara , Versteeg, Anne , Sahgal, Arjun , Rhines, Laurence D. , Schuster, James M. , Weber, Michael H. , Dea, Nicolas , Charest-Morin, Raphaële , Laufer, Ilya , Chou, Dean , Gokaslan, Ziya L. , Fisher, Charles G. , Sciubba, Daniel M. , Tumor, on behalf of the AO Spine Knowledge Forum, Versteeg, Anne L. , Goodwin, C. Rory , Lazáry, Áron , Boriani, Stefano , Bettegowda, Chetan , Fehlings, Michael G. , Arnold, Paul M. , Shin, John H. , Clarke, Michelle J. , Tumor, on behalf of the AO Spine Knowledge Forum

Mayo Clinic

Spine | December 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/brs.0000000000004910 | PMID 38149519 Get It

Study Design. Retrospective review of prospective, multicenter and international cohort study. Objective. To describe the effect of gender on HRQoL, clinical outcomes and survival for patients with spinal metastases treated with either surgery and/or radiation. Summary of Background Data. Gender differences in health-related outcomes are demonstrated in numerous studies, with women experiencing worse outcomes and receiving lower standards of care than men, however, the influence that gender has on low health-related quality of life (HRQoL) and clinical outcomes after spine surgery remains unclear. Methods. Patient demographic data, overall survival, treatment details, perioperative complications, and HRQoL measures including EQ-5D, pain NRS, the short form 36 version 2 (SF-36v2) and the Spine Oncology Study Group Outcomes Questionnaire (SOSGOQ2.0) were reviewed. Patients were stratified by sex, and a separate sensitivity analysis that excluded gender-specific cancers (i.e., breast, prostate, etc.) was performed. Results. The study cohort included 207 female and 183 male patients, with age, smoking status, and site of primary cancer being significantly different between the two cohorts (P<0.001). Both males and females experienced significantly improved SOSGOQ2.0, EQ-5D, and pain NRS scores at all study time points from baseline (P<0.001). Upon sensitivity analysis, (gender-specific cancers removed from analysis), the significant improvement in SOSGOQ physical, mental, and social subdomains and on SF-36 domains disappeared for females. Males experienced higher rates of postoperative complications. Kaplan-Meier survival analysis of both the overall and sensitivity analysis cohorts showed females lived longer than males after treatment (P=0.001 and 0.043, respectively). Conclusion. Both males and females experienced significantly improved HRQoL scores after treatment, but females demonstrated longer survival and a lower complication rate. This study suggests that gender may be a prognostic factor in survival and clinical outcomes for patients undergoing treatment for spine metastases and should be taken into consideration when counseling patients accordingly.
Treatment of intramedullary spinal cord tumors: a modified Delphi technique of the North American Spine Society Section of Spine Oncology
Pennington, Zach , Elsamadicy, Aladine A. , Dea, Nicolas , Desai, Atman , Gokaslan, Ziya L. , Hsu, Wesley , Krishnaney, Ajit A., Laufer, Ilya , Lo, Sheng-Fu Larry , Macki, Mohamed, Mehta, Ankit I. , Ozturk, Ali K. , Sciubba, Daniel M. , Pennington, Zach , Hersh, Andrew M. , Lubelski, Daniel , Goodwin, C. Rory , Jallo, George I. , Shin, John H. , Soliman, Hesham Magdi

Mayo Clinic

Journal of Neurosurgery: Spine | October 13, 2023 | Volume: 40 | Issue: 1 | Pages: 1-10

10.3171/2023.8.spine23190 | PMID 37856379 Get It

OBJECTIVE Intramedullary spinal cord tumors (IMSCTs) are rare tumors with heterogeneous presentations and natural histories that complicate their management. Standardized guidelines are lacking on when to surgically intervene and the appropriate aggressiveness of resection, especially given the risk of new neurological deficits following resection of infiltrative tumors. Here, the authors present the results of a modified Delphi method using input from surgeons experienced with IMSCT removal to construct a framework for the operative management of IMSCTs based on the clinical, radiographic, and tumor-specific characteristics. METHODS A modified Delphi technique was conducted using a group of 14 neurosurgeons experienced in IMSCT resection. Three rounds of written correspondence, surveys, and videoconferencing were carried out. Participants were queried about clinical and radiographic criteria used to determine operative candidacy and guide decision-making. Members then completed a final survey indicating their choice of observation or surgery, choice of resection strategy, and decision to perform duraplasty, in response to a set of patient- and tumor-specific characteristics. Consensus was defined as ≥ 80% agreement, while responses with 70%–79% agreement were defined as agreement. RESULTS Thirty-six total characteristics were assessed. There was consensus favoring surgical intervention for patients with new-onset myelopathy (86% agreement), chronic myelopathy (86%), or progression from mild to disabling numbness (86%), but disagreement for patients with mild numbness or chronic paraplegia. Age was not a determinant of operative candidacy except among frail patients, who were deemed more suitable for observation (93%). Well-circumscribed (93%) or posteriorly located tumors reaching the surface (86%) were consensus surgical lesions, and participants agreed that the presence of syringomyelia (71%) and peritumoral T2 signal change (79%) were favorable indications for surgery. There was consensus that complete loss of transcranial motor evoked potentials with a 50% decrease in the D-wave amplitude should halt further resection (93%). Preoperative symptoms seldom influenced choice of resection strategy, while a distinct cleavage plane (100%) or visible tumor-cord margins (100%) strongly favored gross-total resection. CONCLUSIONS The authors present a modified Delphi technique highlighting areas of consensus and agreement regarding surgical management of IMSCTs. Although not intended as a substitute for individual clinical decision-making, the results can help guide care of these patients. Additionally, areas of controversy meriting further investigation are highlighted.
Introduction. Machine learning in neurosurgery: transitioning to a new era of contemporary medicine
Bydon, Mohamad , Timmons, Shelly D. , Potts, Eric A. , Chan, Andrew K. , Shin, John H.

Mayo Clinic

Neurosurgical Focus | June 1, 2023 | Volume: 54 | Issue: 6 | Pages: E1

10.3171/2023.3.focus23210 | PMID 37283441 Get It

Socioeconomic and Racial/Ethnic Disparities in Perception of Health Status and Literacy in Spine Oncological Patients
Elsamadicy, Aladine A. , Wang, Chelsea, Craft, Samuel , Rajjoub, Rami , Pennington, Zach , Lo, Sheng-Fu Larry , Mendel, Ehud , Sciubba, Daniel M. , Pennington, Zach , Reeves, Benjamin C. , Sherman, Josiah , Koo, Andrew B. , Hersh, Andrew M. , Shin, John H.

Mayo Clinic

Spine | May 10, 2023 | Volume: 48 | Issue: 15 | Pages: 1107-1115

10.1097/brs.0000000000004712 | PMID 37163649 Get It

Study Design. A cross-sectional study was performed using the National Institutes of Health All of Us survey database. Objective. The aim of this study was to assess socioeconomic and racial disparities in the perception of personal health, health literacy, and healthcare access among spine oncology patients. Summary of Background Data. Racial, ethnic, and socioeconomic disparities in health literacy and perception of health status have been described for many disease processes. However, few studies have assessed the prevalence of these disparities among spine oncology patients. Methods. Adult spine oncology patients, identified using ICD-9/10-CM codes, were categorized by race/ethnicity: White/Caucasian (WC), Black/African-American (BAA), and Non-White Hispanic (NWH). Demographics and socioeconomic status were assessed. Questionnaire responses regarding baseline health status, perception of health status, health literacy, and barriers to healthcare were compared. Results. Of the 1,175 patients identified, 207 (17.6%) were BAA, 267 (22.7%) were NWH, and 701 (59.7%) were WC. Socioeconomic status varied among cohorts, with WC patients reporting higher levels of education (P<0.001), annual income greater than $50K (P<0.001), and home ownership (P<0.001). BAA and NWH patients reported greater rates of 7-day “Severe fatigue” (P<0.001) and “10/10 pain” (P<0.001) and lower rates of “Completely” able to perform everyday activities (P<0.001). WC patients had a higher response rate for “Excellent/Very Good” regarding their own general health (P<0.001) and quality (P<0.001). The WC cohort had a significantly higher proportion of patients responding “Never” when assessing difficulty understanding (P<0.001) and needing assistance with health materials (P<0.001). BAA and NWH were significantly less likely to report feeling “Extremely” confident with medical forms (P<0.001). BAA and NWH had significantly higher response rates to feeling “Somewhat Worried” about healthcare costs (P<0.001) and with delaying medical care given “Can’t Afford Co-pay” (P<0.001). Conclusion. We identified disparities in perception of health status, literacy, and access among spine oncology patients. Level of Evidence. 4
HEARING LOSS AND INCIDENT DEMENTIA OVER 7 YEARS IN BLACK AND WHITE OLDER ADULTS IN ARIC-NCS
Reed, Nicholas S. , Sharrett, Richey, Lin, Frank R. , Shin, John H. , Jiang, Kening , Knopman, David S. , Mosley, Thomas H. , Deal, Jennifer A.

Mayo Clinic

Innovation in Aging | December 20, 2022 | Volume: 6 | Issue: Supplement_1 | Pages: 238-238

10.1093/geroni/igac059.945 Get It

Abstract Hearing loss is a risk factor for dementia; whether this association differs by race is unknown. Although hearing loss is less prevalent in Blacks than Whites, we hypothesized the hearing loss-dementia relationship is stronger in Blacks. All-cause dementia and mild cognitive impairment (MCI) were adjudicated using longitudinal cognitive data. Hearing was measured using pure tone better-ear thresholds (0.5-4 kHz). Cox proportional hazards models adjusted for demographic and clinical covariates and included an interaction term between hearing and race. In 3,605 participants from a population-based cohort (68-89 years, 23% Black, 59% female), estimates for 7-year dementia risk per 10 decibels increase in hearing loss were stronger in Blacks (hazard ratio [HR]:1.24, 95% Confidence Interval (CI):1.07,1.43) than Whites (HR:1.07; 95%CI:0.96,1.19). Hearing loss is a risk factor for dementia in Black Americans. These findings emphasize the need to address existing racial disparities in hearing healthcare.
Improved Glycemia with Hybrid Closed-Loop Versus Continuous Subcutaneous Insulin Infusion Therapy: Results from a Randomized Controlled Trial
Grunberger, George , Weinstock, Ruth S. , Hirsch, Irl B. , DiMeglio, Linda A. , Philis‐Tsimikas, Athena , Kipnes, Mark, Liljenquist, David R., Brazg, Ronald, Kudva, Yogish C. , Buckingham, Bruce A. , Carlson, Anders L. , Criego, Amy , Christiansen, Mark P., Kaiserman, Kevin B. , Forlenza, Gregory P. , Bode, Bruce W. , Slover, Robert H., Keiter, Ashleigh , Ling, Chenxiao , Marinos, Briggitte, Cordero, Toni L. , Shin, John , Lee, Scott W., Rhinehart, Andrew S., Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Downs, Ashleigh, Lange, Samantha , Jost, Emily , KARAMI, ANGELA J., Hamill, Donna, Simha, Vinaya , Desjardins, Donna, Spitzer, Shelly McCrady, Reid, Corey, Kaur, Ravinderjeet, Malone, Halvorson, Mary, Ekhlaspour, Laya , Weir, Christine, Casaubon, Luis, Ang, Lynn , Plunkett, Cindy, Recklein, Carol, Clifton, Mary Jane, Weinstock, Ruth S , Hirsch, Irl B , Kudva, Yogish C. , McGill, Janet B. , Forlenza, Gregory P , Cordero, Toni L , Vigersky, Robert A , Philis-Tsimikas, Athena , Buckingham, Bruce , DiMeglio, Linda , Garg, Satish K. , Lawson, Margaret L. , Pop‐Busui, Rodica , Griffin, Kurt , Vigersky, Robert A. , Group, for the Adult and Pediatric MiniMed™ HCL Outcomes 6-month RCT: HCL versus CSII Control Study, Kaur, Ravinder Jeet , Malone, Stout, Kara Mizokami , Plunkett, Cindy, Williams, Brittany

Mayo Clinic

Diabetes Technology & Therapeutics | December 6, 2022 | Volume: 25 | Issue: 1 | Pages: 1-12

10.1089/dia.2022.0421 | PMID 36472543 Get It

Utilization of Machine Learning to Model Important Features of 30-day Readmissions following Surgery for Metastatic Spinal Column Tumors: The Influence of Frailty
Elsamadicy, Aladine A. , Reeves, Benjamin C. , Cross, James M. , Hersh, Andrew M. , Hengartner, Astrid C. , Karhade, Aditya V. , Pennington, Zach , Lo, Sheng-Fu Larry , Gokaslan, Ziya L. , Mendel, Ehud , Sciubba, Daniel M. , Hersh, Andrew , Hengartner, Astrid , Karhade, Aditya V , Pennington, Zach , Sciubba, Daniel , Koo, Andrew B. , Akinduro, Oluwaseun O. , Shin, John H.

Mayo Clinic

Global Spine Journal | November 1, 2022 | Volume: 14 | Issue: 4 | Pages: 1227-1237

10.1177/21925682221138053 | PMID 36318478 Get It

Study Design Retrospective cohort study Objective The aim of this study was to determine the relative importance and predicative power of the Hospital Frailty Risk Score (HFRS) on unplanned 30-day readmission after surgical intervention for metastatic spinal column tumors. Methods All adult patients undergoing surgery for metastatic spinal column tumor were identified in the Nationwide Readmission Database from the years 2016 to 2018. Patients were categorized into 3 cohorts based on the criteria of the HFRS: Low(<5), Intermediate(5-14.9), and High(≥ 15). Random Forest (RF) classification was used to construct predictive models for 30-day patient readmission. Model performance was examined using the area under the receiver operating curve (AUC), and the Mean Decrease Gini (MDG) metric was used to quantify and rank features by relative importance. Results There were 4346 patients included. The proportion of patients who required any readmission were higher among the Intermediate and High frailty cohorts when compared to the Low frailty cohort ( Low:33.9% vs. Intermediate:39.3% vs. High:39.2%, P < .001). An RF classifier was trained to predict 30-day readmission on all features (AUC = .60) and architecturally equivalent model trained using only ten features with highest MDG (AUC = .59). Both models found frailty to have the highest importance in predicting risk of readmission. On multivariate regression analysis, Intermediate frailty [ OR:1.32, CI(1.06,1.64), P = .012] was found to be an independent predictor of unplanned 30-day readmission. Conclusion Our study utilizes machine learning approaches and predictive modeling to identify frailty as a significant risk-factor that contributes to unplanned 30-day readmission after spine surgery for metastatic spinal column metastases.
Evaluation of Extended Infusion Set Performance in Adults with Type 1 Diabetes: Infusion Set Survival Rate and Glycemic Outcomes from a Pivotal Trial
Brazg, Ron, Bhargava, Anuj , Thrasher, James, Latif, Kashif, Bode, Bruce W. , Bailey, Timothy S. , Horowitz, Barry , Cavale, Arvind R., Kudva, Yogish C. , Kaiserman, Kevin B. , Grunberger, George , Reed, John Chip, CHATTARAJ, SARNATH , ZHANG, GINA , Shin, John , Chen, Vivian , Lee, Scott W., Cordero, Toni L. , Rhinehart, Andrew S., Buckingham, Bruce A. , Bailey, Timothy S , Horowitz, Barry S , Kudva, Yogish C. , Cordero, Toni L , Vigersky, Robert A , Buckingham, Bruce , Garg, Satish K. , Reed, John H. Chip, Vigersky, Robert A.

Mayo Clinic

Diabetes Technology & Therapeutics | March 9, 2022 | Volume: 24 | Issue: 8 | Pages: 535-543

10.1089/dia.2021.0540 | PMID 35263188 Get It

Background: Standard insulin infusion sets (IISs) are to be replaced every 2 to 3 days to avoid complications and diabetic ketosis due to set failure. This pivotal trial evaluated the safety and performance of a new extended-wear infusion set (EIS) when used for 7 days by adults with type 1 diabetes (T1D). Methods: This single-arm, nonrandomized trial enrolled adults (18–80 years of age) with T1D, who used their own MiniMed™ 670G system with insulin lispro or insulin aspart and the EIS for up to 7 days, across 12 consecutive wears. Safety endpoints included incidence of serious adverse events (SAEs), serious adverse device effects (SADEs), unanticipated adverse device effects (UADEs), severe hypoglycemia (SevHypo), severe hyperglycemia (SevHyper), diabetic ketoacidosis (DKA), and skin infection. The EIS failure rate due to unexplained hyperglycemia (i.e., suspected occlusion), the overall EIS survival rate, glycemic control outcomes (i.e., A1C, mean sensor glucose and time spent in established glucose ranges), total daily insulin delivered, and satisfaction with the EIS were determined. Results: The intention to treat population ( n = 259, 48% men, 45.0 ± 14.1 years) wore a total of 3041 EIS devices. No SADE, UADE, or DKA events was reported. Overall rates of SAEs, SevHypo, SevHyper, and skin infection were 3.8, 2.5, 104.1, and 20.1 events per 100 participant-years. The rate of EIS failure due to unexplained hyperglycemia at the end of day 7 was 0.1% (95% confidence interval [CI]: 0.03–0.51) and 0.4% (95% CI: 0.16–1.00) for insulin lispro and aspart use, respectively. Overall EIS survival rate at the end of day 7 was 77.8% (95% CI: 76.2–79.3), glycemic control did not change, and participants reported greater satisfaction with the EIS compared with standard IISs worn before the study ( P < 0.001). Conclusions: This investigation demonstrates that the EIS, when worn for up to 7 days, was safe and rated with high satisfaction, without adversely affecting glycemic control in adults with T1D. Clinical Trial Registration number: NCT04113694 ( https://clinicaltrials.gov/ct2/show/NCT04113694 ).